Tehran hit by unprecedented Israeli strikes as U.S. peace talks stall and Hormuz deadline pushed again
Read More 5 minute read Pharma Industry News Camurus resubmits Oclaiz for FDA review as subcutaneous acromegaly therapy eyes June 2026 decision Camurus's Oclaiz is back in FDA review for acromegaly. Find out what the June 2026 decision could mean for U.S. access and endocrine market disruption. bySrinathJanuary 12, 2026